Patients eligible for fam-trastuzumab deruxtecan-nxki typically have metastatic HER2-positive breast cancer that has progressed despite previous treatments. Eligibility criteria may vary, so it is important for patients to undergo thorough genetic testing and evaluation by an oncologist to determine if they are suitable candidates for this therapy.
